http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Nevro Introduces HFX, New Comprehensive Brand Identity Combining Nevro's Innovative Technologies, Advanced Therapies and End-to-End Patient Support
-
Nevro Appoints Jon R. Shear as Vice President, Corporate Development
-
Nevro to Present at BofA Securities 2021 Virtual Health Care Conference
-
Nevro to Report First Quarter 2021 Financial Results
-
Nevro (NVRO) Announces Publication Of Landmark SENZA-PDN Clinical Trial Results In JAMA Neurology
-
Nevro Announces Publication Of Landmark SENZA-PDN Clinical Trial Results In JAMA Neurology
-
Nevro Reports Fourth Quarter and Full Year 2020 Financial Results
-
Nevro to Present at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference
-
Nevro to Present at 10th Annual SVB Leerink Global Healthcare Conference
-
Nevro to Report Fourth Quarter and Full-Year 2020 Financial Results
-
Clinical Data Presented at 2021 North American Neuromodulation Society (NANS) Virtual Meeting Reinforce Significant Benefits of Nevro's HF10® Therapy
-
Nevro to Highlight New Clinical Evidence at the 2021 North American Neuromodulation Society (NANS) Virtual Meeting
-
Nevro (NVRO) Announces Preliminary Q4 Revenue
-
Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2020 Revenue
-
Nevro (NVRO) Submits FDA Pre-Market Approval Supplement for HF10 Therapy
-
Nevro Announces FDA Submission for HF10® Therapy in Patients with Painful Diabetic Neuropathy
-
Nevro to Host Virtual Investor Briefing at 2021 North American Neuromodulation Society (NANS) Virtual Conference
-
Nevro to Present at 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021
-
Boston Scientific Announces Stipulation Of Dismissal Of Nevro Corporation's Patent Infringement Case In California
-
Nevro Announces Agreement to Conclude Its Patent Lawsuit in the Northern District of California Against Boston Scientific
-
Nevro Appoints Julie D. Dewey as Vice President, Investor Relations and Corporate Communications
-
Nevro to Participate in Citi Bank Head Shoulders Knees and Toes Conference Call Series on November 30th
-
Nevro Announces Abstract Presentations for PDN and NSRBP Trials Have Been Accepted for the Late Breaking Trials Plenary Session at NANS 2021 Conference
-
Nevro Announces Third Quarter 2020 Financial Results
-
Nevro to Report Third Quarter 2020 Financial Results
-
Nevro (NVRO) Initiates Plan for Manufacturing Operations in Costa Rica to Support Future Growth
-
Nevro Initiates Plan for Manufacturing Operations in Costa Rica to Support Future Growth
-
Nevro to Present at Upcoming Conferences
-
Nevro to Present at Canaccord Genuity 40th Annual Virtual Growth Conference
-
Nevro Announces Second Quarter 2020 Financial Results
-
Nevro to Report Second Quarter 2020 Financial Results
-
Nevro (NVRO) Announces Roderick MacLeod as CFO
-
Nevro Appoints Finance Executive Roderick MacLeod as Chief Financial Officer
-
Nevro Announces CE Mark Approval of Senza® Omnia™ Spinal Cord Stimulation System to Treat Chronic Pain
-
Nevro Reports First Quarter 2020 Financial Results
-
Nevro To Participate in Upcoming May Conferences
-
Nevro to Report First Quarter 2020 Financial Results
-
Nevro Announces Federal Circuit Rules in its Favor and Upholds the Validity of Nevro's Patent Claims In Its Litigation Against Boston Scientific
-
Nevro Announces the Full Exercise of the Underwriter's Option to Purchase Additional Common Stock and the Underwriter's Over-allotment Option to Purchase Additional Convertible Senior Notes
-
Nevro (NVRO) Announces Pricing of Public Offerings of Common Stock and Convertible Senior Notes
-
Nevro Announces Pricing of Public Offerings of Common Stock and Convertible Senior Notes
-
Nevro (NVRO) Announces Proposed 1.625M Shares Common Offering
-
Nevro Announces Proposed Public Offering of Common Stock and Convertible Senior Notes
-
Nevro (NVRO) withdraws its previously announced annual guidance for 2020
-
Nevro Provides First Quarter and FY2020 Update
-
Nevro (NVRO) Files Lawsuit for Patent Infringement Against Nalu Medical in U.S.
-
Nevro and Stimwave Reach Worldwide Settlement in Patent Infringement Lawsuit: Stimwave Agrees to a Permanent Injunction
-
Nevro Files Lawsuit for Patent Infringement Against Nalu Medical in the U.S.
-
Nevro Reports Fourth Quarter and Full Year 2019 Financial Results
-
Nevro to Report Fourth Quarter and Full Year 2019 Financial Results

